Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov 10;2010(11):CD008243.
doi: 10.1002/14651858.CD008243.pub2.

Percutaneous lines for delivering intravenous antibiotics in people with cystic fibrosis

Affiliations

Percutaneous lines for delivering intravenous antibiotics in people with cystic fibrosis

Andrew P Prayle et al. Cochrane Database Syst Rev. .

Abstract

Background: Percutaneous long lines (long intravenous lines) and short intravenous lines (also termed cannulae) are both used to deliver intravenous antibiotics in cystic fibrosis to treat respiratory exacerbations of the disease. The perceived advantage of a long intravenous line is a greater duration of line function, which has to be balanced against a technically more challenging insertion procedure, and the possibility of more discomfort on insertion.

Objectives: To compare long intravenous lines with short intravenous lines in people with cystic fibrosis receiving intravenous antibiotics, in terms of lifespan of the line, ease of insertion, complication rates of the line and patient satisfaction. This will help patients and clinicians choose between devices.

Search strategy: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Date of most recent search: 26 August 2010.

Selection criteria: Randomised studies comparing long intravenous lines lines with short intravenous lines or comparing different types of long intravenous lines.

Data collection and analysis: We identified two studies, one comparing long intravenous lines with short intravenous lines, and one comparing two different types of long intravenous lines.

Main results: Two studies (67 participants) were included in the review. Based on the published reports, both studies had potential for bias in several domains. There is some evidence that long intravenous lines are superior to short intravenous lines. One study of 20 participants found that the lifespan of a long intravenous line is longer than that of a short intravenous line, and that participants preferred the long intravenous lines to short intravenous lines. A further study of 47 participants found no difference in lifespan, or participant preference when comparing two different long intravenous lines (the Hydrocath and Vygon EC). Neither study was powered to detect differences in serious complications of the devices.

Authors' conclusions: There is some evidence to support the use of long intravenous lines rather than short intravenous lines, in terms of lifespan of the line and patient satisfaction. There is no evidence to suggest that any one type of long intravenous line is superior, and currently choice of line should be determined by operator and patient preference. There are numerous devices available which are used in cystic fibrosis. Further research is required to identify clinically important differences between these devices.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Long IV line versus short IV line, Outcome 1 Patient satisfaction.
2.1
2.1. Analysis
Comparison 2 Long IV lines compared, Outcome 1 Complications of the long line.
2.2
2.2. Analysis
Comparison 2 Long IV lines compared, Outcome 2 Complication necessitating removal of the line.
2.3
2.3. Analysis
Comparison 2 Long IV lines compared, Outcome 3 Completion of a course of antibiotics with a single long iv line.
2.4
2.4. Analysis
Comparison 2 Long IV lines compared, Outcome 4 Lifespan of the long iv line.

Update of

  • doi: 10.1002/14651858.CD008243

Similar articles

References

References to studies included in this review

Lacy 1996 {published data only (unpublished sought but not used)}
    1. Lacy DE, Spencer DA, Venkararaman M, Ruiz G, Weller P. Comparison of Two Percutaneous "Midline" Catheters in Cystic Fibrosis. Journal of Intravenous Nursing 1996;16(1):28‐31. - PubMed
Williams 1988 {published data only (unpublished sought but not used)}
    1. Williams J, Smith HL, Woods CG, Weller PH. Silastic catheters for antibiotics in cystic fibrosis. Archives of Diseases in Childhood 1988;63(6):658‐9. - PMC - PubMed

References to studies awaiting assessment

Pradeepkumar 1992 {published data only (unpublished sought but not used)}
    1. Pradeepkumar VK, Waseem R, Shortt C, Barry D, Watson JBG. Home intravenous therapy using a silastic long line catheter in cystic fibrosis patients. Irish Medical Journal 1992;85(3):110‐1. - PubMed

Additional references

A‐Rahman 2003
    1. A‐Rahman AKM, Spencer D. Totally implantable vascular access devices for cystic fibrosis. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858] - DOI - PubMed
Abedin 2008
    1. Abedin S, Kapoor G. Peripherally inserted central venous catheters are a good option for prolonged venous access in children with cancer. Pediatric Blood & Cancer 2008;5(2):251‐5. - PubMed
Chmiel 2003
    1. Chmiel JF, Davis PB. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?. Respiratory Research 2003;4:8. - PMC - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2008a
    1. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Higgins 2008b
    1. Higgins JPT, Deeks JJ, Altman DG, on behalf of the Cochrane Statistical Methods Group. Chapter 13: Special Topics in Statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Higgins 2008c
    1. Sterne JAC, Egger M, Moher D, on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing Reporting Biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Jones 2000
    1. Jones SP, Kaslovsky RA. Successful utilization of peripheral inserted central catheters (PICC) for iv antibiotic therapy in pediatric patients with cystic fibrosis (CF) [abstract]. Pediatric Pulmonology 2000;Suppl 20:339.
Lau 2006
    1. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333(7658):597‐600. - PMC - PubMed
Mateu 2002
    1. Mateu E, Calafell F, Ramos MD, Casals T, Bertranpetit J. Can a place of origin of the main cystic fibrosis mutations be identified?. American Journal of Human Genetics 2002;70(1):257‐64. - PMC - PubMed
O'Sullivan 2009
    1. O'Sullivan BP, Freedman SD. Cystic Fibrosis. Lancet 2009;373(9678):1891‐904. - PubMed
Rosenstein 1998
    1. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. Journal of Pediatrics 1998;132(4):589‐95. - PubMed
UK Cystic Fibrosis Trust Antibiotic Working Group
    1. UK Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic Treatment for Cystic Fibrosis. Report of the UK CysticFibrosis Trust Antibiotic Working Group, Third Edition May 2009.

Publication types

MeSH terms

Substances